MEDICAL MATERIAL AND PREPARATION METHOD THEREFOR

Abstract

Disclosed are a medical material and a preparation method therefor. The preparation method comprises the following steps: S1: adding a nano montmorillonite into a solution of a silane coupling agent, followed by stirring, rinsing, and drying to obtain a modified nano montmorillonite; and S2: mixing a thermoplastic elastomer with the modified nano montmorillonite to obtain the medical material. The medical material prepared according to the present invention improves the modulus, breaking strength and flexural modulus of the thermoplastic elastomer, and broadens the application of the thermoplastic elastomer in the field of high-end minimally invasive interventional medical products; simplifies a production process; and increases productivity.

Claims

1. A method for preparing a medical material, comprising steps of: S1, adding nano-montmorillonite to a solution of a silane coupling agent, followed by stirring, washing, and drying to obtain a modified nano-montmorillonite; and S2, mixing a thermoplastic elastomer with the modified nano-montmorillonite, followed by stirring to obtain the medical material.

2. The method according to claim 1, wherein the silane coupling agent in the step S1 is at least one of γ-aminopropyltriethoxysilane, γ-(2,3-glycidoxy)propyltrimethoxysilane or γ-(methacryloxy)propyltrimethoxysilane.

3. The method according to claim 1, wherein the nano-montmorillonite in the step S1 has a particle size of 1 nm-100 nm, and a volume density of 0.24 gms/cc-0.32 gms/cc.

4. The method according to claim 1, wherein the step S1 comprises: adding the nano-montmorillonite to the solution of the silane coupling agent, followed by stirring at a constant temperature of 50° C.-70° C.; washing and drying a resultant which is obtained after adding the nano-montmorillonite, to obtain the modified nano-montmorillonite.

5. The method according to claim 1, wherein the thermoplastic elastomer is at least one of polyether block amide, thermoplastic polyurethane, styrene block copolymer, styrene-butadiene-styrene block copolymer or octene copolymer.

6. The method according to claim 1, wherein in the step S2, the modified nano-montmorillonite and the thermoplastic elastomer are in a mass ratio of 1%-5%.

7. The method according to claim 1, wherein the step S2 comprises: adding the thermoplastic elastomer and the modified nano-montmorillonite into a mixer for uniform mixing to obtain a mixture, and extruding the mixture with an extruder.

8. The method according to claim 7, further comprising a step of: S3, washing and condensing the extruded mixture, followed by granulating and drying.

9. The method according to claim 7, wherein the extruding the mixture with the extruder comprises: extruding the mixture with a co-rotating twin-screw extruder, wherein the co-rotating twin-screw extruder has an aspect ratio of a length to a diameter of a screw, of 1:35 to 1:55, runs at a screw speed of 150 rpm to 1000 rpm, and has an extrusion temperature of 180° C. to 230° C., an extruder head pressure of 3 MPa to 5 MPa, and a vacuum pump pressure of 0.8 MPa to 1 MPa.

10. A medical material, wherein the medical material is a blend of a thermoplastic elastomer and nano-montmorillonite, the thermoplastic elastomer has a lamella structure and forms a nano-crystal three-dimensional network structure with the nano-montmorillonite.

11. The medical material according to claim 10, wherein the nano-montmorillonite and the thermoplastic elastomer in the blend of the thermoplastic elastomer and the nano-montmorillonite are in a mass ratio of 1%-5%.

12. The medical material according to claim 10, wherein the thermoplastic elastomer is at least one of polyether block amide, thermoplastic polyurethane, styrene block copolymer, styrene-butadiene-styrene block copolymer or octene copolymer.

13. The medical material according to claim 10, wherein the nano-montmorillonite is nano-montmorillonite modified with a silane coupling agent.

Description

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0021] The present disclosure will be further described below in conjunction with examples.

Example 1

[0022] First, a predetermined amount of a silane coupling agent was added to a prepared mixing solution of absolute ethanol, deionized water and glacial acetic acid, followed by stirring at room temperature for 2-6 hours. Specifically, the silane coupling agent may be KH550 silane coupling agent (γ-aminopropyltriethoxysilane), KH560 silane coupling agent (γ-(2,3-glycidoxy)propyltrimethoxysilane), KH570 silane coupling agent (γ-(methacryloxy)propyltrimethoxysilane) or the like.

[0023] Next, a predetermined amount of nano-montmorillonite was added to the above solution with further stirring at a constant temperature of 50° C.-70° C. for 8-24 hours. The resultant was washed three times with absolute ethanol, and then dried in a vacuum drying oven to obtain a modified nano-montmorillonite.

[0024] Then, dry polyether block amide (PEBA) and the modified nano-montmorillonite were added into a high-speed mixer according to a predetermined mass ratio and mixed uniformly. The nano-montmorillonite has a particle size of 15 nm, and a volume density of 0.24 gms/cc. The PEBA and the modified nano-montmorillonite is in a mass ratio of 100:1. Then, the mixture is extruded by a co-rotating twin-screw extruder. Temperatures of processes during the operating of the extruder are 190° C., 200° C., 210° C., 220° C., respectively. A screw speed is 150 rpm, an extruder head pressure is 3 MPa, and a vacuum pump pressure is 0.81 MPa. In other embodiments, the PEBA can also be replaced by thermoplastic polyurethane elastomer (TPU), styrene block copolymer (SBC), styrene-butadiene-styrene block copolymer (SBS) or octene copolymer (POE) and other thermoplastic elastomer materials.

[0025] Finally, the samples extruded by the co-rotating twin-screw extruder were washed and condensed by water in a water tank, then granulated and dried to obtain a medical material enhanced by the nano-montmorillonite.

Example 2

[0026] The production process of this example was the same as that of Example 1, except that the PEBA and the modified nano-montmorillonite were in a different mass ratio, which is 100:5.

[0027] The nano-montmorillonite is selected in the present disclosure. Compared with ordinary montmorillonite, the nano-montmorillonite has a larger specific surface area. The well-dispersed nano-montmorillonite improves the modulus, fracture strength and flexural modulus of medical polymer materials.

[0028] In the present disclosure, surface modification treatment of the nano-montmorillonite by adding a silane coupling agent such as KH550, KH560 or KH570 increases the compatibility and bonding force of the nano-montmorillonite with the medical polymer materials. The montmorillonite has poor dispersion and compatibility in thermoplastic elastomers, however, hydrophobical modification by using the silane coupling agent can not only improve its lipophilicity, but also enhance its reactivity, allowing it to more easily chemically react with other functional groups, thereby improving the compatibility with other materials.

[0029] Therefore, in the present disclosure, the thermoplastic elastomer is blended with the nano-montmorillonite, and thus is modified by the nano-montmorillonite. The nano-montmorillonite is exfoliated into nano-scale structural sheets in the process of being blended with the thermoplastic elastomer melt, and is uniformly dispersed into the thermoplastic elastomer matrix. In the subsequent extrusion process, under the action of high-stretching, the thermoplastic elastomer spherulites in the blend are transformed into lamellae. With the lamella structure of the nano-montmorillonite, a nano-crystal three-dimensional network structure is formed from the thermoplastic elastomer and the nano-montmorillonite, thereby significantly improving the modulus, fracture strength and flexural modulus of the thermoplastic elastomer. Through the modification and research of this kind of material, it is applied to a conveyor to improve the delivery and torque performance of the conveyor, so that the conveyor can be used in guiding catheters, drug stent conveyors, dilatation balloon catheters, angiographic catheters, electrophysiological catheters and other products.

[0030] Although the present disclosure has been disclosed as above embodiments, they are not intended to limit the present disclosure. Some modifications and improvements can be made by one skilled in the art without departing from the spirit and scope of the present disclosure. Thus, the protection scope of the present disclosure should be defined by the claims.